US FDA: Carcinogenic Potency Categorization Approach for Nitrosamine Impurities
Recommendation

6/7 October 2026
In January 2025, the US FDA has published in its newsroom on the CDER website the article called "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach". It is structured in the following chapters and passages:
- Background
- Materials and Methods
- Results
A) α-Hydrogen features in the format "n,n" where the lowest number of hydrogens is listed first
B) Deactivating features
C) Activating features - Discussion
- Other resources
The article clearly explains the historical background of developing and establishing the "Carcinogenic Potency Categorization Approach (CPCA)" and provides an overview of deactivating and activating features in a listed order.
The complete article "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach" can be checked in the newsroom of CDER's website.
Related GMP News
20.08.2026IPEC: New Stability Guide for Excipients Published
12.08.2026FDA Warning Letter for an Indian API Manufacturer
29.07.2026EPRS publishes a Briefing Paper on PFAS
15.07.2026GMP for Active Substances - What are the fundamental Requirements of the ICH Q7 Guideline? - Part 2
08.07.2026GMP for Active Substances - What are the fundamental Requirements of the ICH Q7 Guideline? - Part 1
10.06.2026What are the Requirements for Testing for Impurities in the Pharmaceutical Industry?


